Diagnostics acquisition
Thermo Fisher Scientific has completed its acquisition of blood test systems provider Phadia.
Thermo Fisher Scientific has completed its acquisition of blood test systems provider Phadia. Phadia is based in Uppsala, Sweden and develops, manufactures and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases.
"We are pleased to complete the acquisition of Phadia, which significantly enhances our presence in high-growth specialty diagnostics markets by adding leading allergy and autoimmunity diagnostic tests," said Marc N. Casper, president and chief executive officer of Thermo Fisher. "Phadia provides us with growth opportunities in an under-penetrated US market and allows us to leverage our strong presence in emerging geographic markets."
Phadia will become part of Thermo Fisher's Specialty Diagnostics business.
For more information on the companies visit their websites at www.phadia.com and www.thermofisher.com
LC–MS/MS-Based System Used to Profile Ceramide Reactions to Diseases
April 26th 2024Scientists from the University of Córdoba in Córdoba, Spain recently used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to comprehensively profile human ceramides to determine their reactions to diseases.
High-Throughput 4D TIMS Method Accelerates Lipidomics Analysis
April 25th 2024Ultrahigh-pressure liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) had been previously proposed for untargeted lipidomics analysis, but this updated approach was reported by the authors to reduce run time to 4 min.
